X-101398419-A-G
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM2PP3_StrongPP5_Moderate
The NM_000169.3(GLA):āc.950T>Cā(p.Ile317Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000912 in 1,097,023 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ).
Frequency
Consequence
NM_000169.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GLA | NM_000169.3 | c.950T>C | p.Ile317Thr | missense_variant | 6/7 | ENST00000218516.4 | NP_000160.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GLA | ENST00000218516.4 | c.950T>C | p.Ile317Thr | missense_variant | 6/7 | 1 | NM_000169.3 | ENSP00000218516.4 | ||
RPL36A-HNRNPH2 | ENST00000409170.3 | c.300+2962A>G | intron_variant | 4 | ENSP00000386655.4 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome AF: 9.12e-7 AC: 1AN: 1097023Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 362397
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Fabry disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 22, 2019 | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed to segregate with Fabry disease in a family (PMID:Ā¬ā 23305247) and has been observed in mutiple individuals affected with Fabry disease (PMID: 12175777, 11914245, 17040996, 18023222). This variant is not present in population databases (ExAC no frequency). This sequence change replaces isoleucine with threonine at codon 317 of the GLA protein (p.Ile317Thr). The isoleucine residue is highly conserved and there is a moderate physicochemical difference between isoleucine and threonine. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 30, 2024 | The p.I317T pathogenic mutation (also known as c.950T>C), located in coding exon 6 of the GLA gene, results from a T to C substitution at nucleotide position 950. The isoleucine at codon 317 is replaced by threonine, an amino acid with similar properties. This alteration has been reported in numerous individuals with Fabry disease, including individuals with deficient alpha-galactosidase enzyme activity and symptoms, such as renal insufficiency and cardiac disease (Sachdev B et al. Circulation, 2002 Mar;105:1407-11; Shabbeer J et al. Mol Genet Metab, 2002 May;76:23-30; Merta M et al. Nephrol Dial Transplant, 2007 Jan;22:179-86; Auray-Blais C et al. Mol Genet Metab, 2008 Mar;93:331-40; Chen X et al. ESC Heart Fail, 2021 Dec;8:5436-5444; Effraimidis G et al. PLoS One, 2022 Nov;17:e0277767; Nakamura K et al. Mol Genet Metab Rep, 2023 Sep;36:100983). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at